Crescent Biopharma (CBIO) Total Non-Current Liabilities (2015 - 2024)

Crescent Biopharma (CBIO) has 10 years of Total Non-Current Liabilities data on file, last reported at $47.1 million in Q4 2024.

• Total Non-Current Liabilities for Q4 2024 came in at $47.1 million, up 582.35% year-over-year; the trailing twelve-month figure through Dec 2024 was $47.1 million (up 582.35% YoY), and the FY2024 annual result was $47.1 million, up 582.35% from the prior year.
• Total Non-Current Liabilities grew to $47.1 million in Q4 2024 per CBIO's latest filing, from $4.3 million in the prior quarter.
• Over five years, Total Non-Current Liabilities peaked at $47.1 million in Q4 2024 and troughed at $4.3 million in Q3 2024.
• A 5-year average of $11.4 million and a median of $10.1 million in 2021 frame the typical range for Total Non-Current Liabilities.
• The sharpest annual moves came in 2023 and 2024: Total Non-Current Liabilities slumped 49.83% in 2023, then soared 582.35% in 2024.
• A 5-year view of Total Non-Current Liabilities shows it stood at $14.6 million in 2020, then fell by 12.8% to $12.7 million in 2021, then tumbled by 30.31% to $8.9 million in 2022, then retreated by 22.28% to $6.9 million in 2023, then soared by 582.35% to $47.1 million in 2024.
• Business Quant data shows CBIO's Total Non-Current Liabilities at $47.1 million in Q4 2024, $4.3 million in Q3 2024, and $4.4 million in Q2 2024.